Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

e opinion was based on data from the Phase II study (PCYC-1104) in MCL, a Phase III RESONATE™ study (PCYC-1112-CA) and a Phase II study (PCYC-1102) in CLL.

The EMA is a decentralized agency of the European Union responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the 28 countries of the European Union. The positive opinion of the EMA's CHMP will be reviewed by the European Commission, and a final decision on IMBRUVICA is anticipated later this year. In addition to European markets, a worldwide regulatory filing program for IMBRUVICA currently is underway.

Clinical UpdateIMBRUVICA (ibrutinib) clinical trials are active in all regions including US, Europe, Asia Pacific, Canada and Latin America. Currently IMBRUVICA is being developed in 8 different B-cell malignancies. There are 12 Phase III clinical trials initiated with IMBRUVICA and a total of 50 trials are registered on www.clinicaltrials.gov, of which 23 are investigating combination regimens while the remaining 27 are investigating IMBRUVICA monotherapy. The total planned enrollment for all of our clinical studies investigating IMBRUVICA is approximately 7,200 patients. As of today there are seven Phase III studies focused on patients with CLL, two designed for patients with MCL, one for patients with diffuse large B-cell lymphoma, one for patients with follicular lymphoma and one for Waldenstroms macroglobulinemia. To date, over 3,300 patients have been treated in Company-sponsored trials which are being conducted in over 35 countries around the globe and which involve more than 800 principal investigators.

During the second quarter, we initiated a Company-sponsored, randomized, double-blind, placebo-controlled, Phase III study of IMBRUVICA or placebo in combination with rituximab in previously treated Waldenstrom's Macroglobulinemia patients. The total planned enrollment for this study i
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
3. WuXi PharmaTech to Partner with Pharmacyclics
4. Pharmacyclics Reports Third Quarter 2013 Results
5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
6. Pharmacyclics Reports Second Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
8. Pharmacyclics Reports First Quarter 2013 Results
9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015  EndoChoice Holdings, Inc. (NYSE:  GI) announced ... financial results on Thursday, August 6, 2015 before the ... conference call on Thursday, August 6, 2015 at 9:00 ... are (866) 807-9684 for domestic callers and (412) 317-5415 ... call will be available on the investor relations section ...
(Date:7/6/2015)... , July 6, 2015 Flower ... fixation concept the FlowerCube™, announced today that it ... the opportunity for significant expansion of the innovative ... The approval encompasses Flower Orthopedics, entire product ... for upper and lower extremities. Consisting of more ...
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/bkw8kk/pharmaceutical ) has ... in North America 2015-2019" report to their offering. ... North America to grow at a CAGR ... International regulations regarding safe drug delivery are enforced by ... adoption of sustainable packaging. Various raw materials such as ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2Flower Orthopedics cleared to enter the European Union 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3
... The Chinese Biopharmaceutical Association-USA (CBA) successfully held its 16 ... US.   With the theme of ... the conference drew nearly 500 attendees with ... exhibited at the conference, including Chinese leading biotech parks, ...
... The Council on Competitiveness, in partnership with the ... case study today highlighting the potential for high performance ... facing the health care industry. The report, " ... the Delivery of ,Smarter, Health Care ," studies ...
Cached Medicine Technology:Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 3Council on Competitiveness Showcases Power of High Performance Computing in Case Study with GNS Healthcare 2
(Date:7/7/2015)... ... July 07, 2015 , ... Office ... the company’s new Chief Financial Officer, effective July 6th, 2015. Ellen joins Office ... ranging from a multi-billion dollar, global chemical company to early and growth-stage technology ...
(Date:7/7/2015)... Colo. (PRWEB) , ... July ... ... landscape relies on highly educated and motivated leaders with strong managerial expertise ... well they clearly communicate with patients, staff, providers, business partners, insurance companies, ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... management solutions, has announced the release of Service Pack 5600 for its ... a number of enhancements to the already robust capabilities of the reporting ...
(Date:7/7/2015)... ... 2015 , ... On May 29, 2015, Health Canada announced that they had ... claims for gluten free oats and foods that contain them as ingredients. , “We ... (GFCP) to include gluten-free oat products in Canada,” says Frank Massong, VP of Regulatory ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Connexion Point is holding an onsite job ... be held at 1769 Paragon Place, Suite 100, this upcoming Wednesday, July 8, and Thursday, ... fair, Connexion Point will be recruiting new applicants as well as holding onsite interviews. ...
Breaking Medicine News(10 mins):Health News:Office Practicum Announces new CFO 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2
... Gospel to foreign nations fulfilled his heart’s passion for ... in 1998, he experienced severe headaches that eventually forced ... relief for the Garland resident’s cluster headaches, which occurred ... in succession and caused facial throbbing, until he came ...
... high levels of lipoprotein(a), particularly those with high ... risk for cardiovascular events, according to a study ... ,Lipoprotein(a) is a specific class of lipoprotein ... low-density lipoprotein cholesterol (LDL-C), according to background information ...
... preeclamptic pregnancy has improved substantially over the last 35 ... stillbirths// and improvements in clinical management, according to a ... ,Preeclampsia (a potentially dangerous condition that may develop in ... fluid retention, excessive weight gain, and the presence of ...
... low-density lipid “bad” cholesterol and triglycerides, and slightly raises ... study published in the Sept. 1, 2006 issue of ... study gives strong support to the notion that soy ... for the prevention and treatment of high blood cholesterol ...
... hospitals have unearthed the use of tainted human body parts, ... 25 UK hospitals as implants for patients. This information came ... matters of public interest take precedence over issues of secrecy, ... ,This is thought to be the work of ...
... study, frequent short sessions of exercise may be more ... single long session one//. ,This study was ... published in the September issue of the Journal of ... over 80-89 mm Hg, it is a condition called ...
Cached Medicine News:Health News:Different Techniques Can Help Ease Chronic Pain, Return Patients’ Smile 2Health News:Different Techniques Can Help Ease Chronic Pain, Return Patients’ Smile 3Health News:High Levels of Lipoprotein(a) in Women is Associated With Cardiovascular Risk 2Health News:Improvement Seen in Fetal Survival Following Preeclampsia 2Health News:Stolen Body Parts From Human Cadavers used as Implants by 25 UK Hospitals 2
... SPECIFICATIONS Form: Granular, free-flowing powder EEO(-m r ): ... less than or equal to 35.5C Remelt Point ... Strength (1.5%): greater than or equal to 600 ... than or equal to 1500 gm/cm 2 Moisture: ...
... chloride (Cl) ≤ 5000 mg/kg sulfate (SO 4 ) ... Cd ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ... 10 mg/kg K ≤ 50 mg/kg Mg ≤ 5 ... Ni ≤ 5 mg/kg Pb ≤ 5 mg/kg Zn ...
Inquire...
Inquire...
Medicine Products: